CTI Molecular Imaging Acquires Mirada Solutions

KNOXVILLE, Tenn., August 20 -- CTI Molecular Imaging Inc., a provider of positron emission tomography (PET) equipment, molecular probes and services, has acquired Mirada Solutions Ltd., a developer of fusion software applications for medical imaging workstations, for $22 million, the companies announced yesterday.

CTI will incorporate Mirada's image analysis and fusion software into its PET scanner workstations, with the aim of enhancing its analytical and diagnostic capabilities. Mirada, which is a spinout from Oxford University, has developed several products that provide better detection, diagnosis and management of disease through the application of powerful image analysis software to medical images, CTI said.

"Mirada has found an excellent partner in CTI," said Mirada CEO Chris Behrenbruch. "With CTI, we believe our workstation software solutions will help define the market for PET and molecular imaging in the diagnosis of disease and in the development of new applications in pharmaceutical research, disease monitoring and therapy. CTI has built an outstanding direct distribution sales force that will provide an excellent distribution channel for our products."

CTI's PET technology is used in the detection and treatment of cancer, cardiac disease and neurological disorders.

For more information, visit: www.ctimi.com